{
  "abstract": "Cancer immunotherapy with immune checkpoint inhibitors (ICIs), i.e., antibodies targeting inhibitory ICs, such as PD-1, PD-L1, and CTLA-4, have successfully revolutionized cancer treatment. One of the most promising cancer immunotherapies is based on bi-specific T-cell engagers that simultaneously bind with one arm to a tumor-associated antigen on tumor cells and with the other one to the CD3 complex on T cells to form a TCR-MHC-independent immune synapse. We previously generated four novel tribodies, tri-specific antibody derivative constructs, made up of a Fab targeting 5T4, an oncofetal tumor antigen expressed on several types of tumors, an scFv targeting CD3 on T cells, and an additional scFv specific for an immune checkpoint. In particular, the 53L10 tribody, targeting PD-L1, displayed the best binding properties and stronger anti-tumor activity in vitro and in vivo in mouse models. Here, we further investigated the anti-tumor potential of 53L10 by testing its effects on a panel of tumor cell types with a more aggressive profile, including gastric, pancreatic, prostate, ovarian, and epidermoid tumor cells. We found that 53L10 was very effective on these cells by inducing stronger T-cell activation and tumor cell lysis than the parental bi-specific 53P lacking an ICI. To further test its therapeutic potential, we also analyzed its stability and the effects on tumor T-cell infiltration in vivo on a mouse model. 53L10 was found to be stable after incubation in serum at 37 °C for 3 days and induced a more efficient and earlier increase in tumor tissues of both CD4 and CD8 T cells than the parental bi-specific 53P. These findings support further preclinical evaluation of 53L10 as a new tool for multiple solid tumor-targeted therapeutic approaches.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Molecular Medicine and Medical Biotechnologies, University of Naples “Federico II”",
    "Ceinge-Biotecnologie Avanzate s.c.a.r.l.",
    "Chiome Bioscience Inc.",
    "European School of Molecular Medicine, University of Milan"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Margherita Passariello"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Martina Belardo"
    },
    {
      "affs": [
        2
      ],
      "name": "Toshikazu Inoue"
    },
    {
      "affs": [
        2
      ],
      "name": "Kentaro Kajiwara"
    },
    {
      "affs": [
        1,
        3
      ],
      "name": "Rosa Rapuano Lembo"
    },
    {
      "affs": [
        2
      ],
      "name": "Shu-ichi Hashimoto"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Claudia De Lorenzo"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/03cejw790gn6b.bib",
  "cited_by": 0,
  "doi": "10.3389/fimmu.2026.1934039",
  "fulltext_url": "https://europepmc.org/articles/PMC13680437",
  "id": "03cejw790gn6b",
  "issns": [
    "1664-3224"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1934039/full",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7220677065",
  "pdf_url": "https://europepmc.org/articles/PMC13680437?pdf=render",
  "pmcid": "PMC13680437",
  "pmid": "42903181",
  "published": "2026-10-06",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/03cejw790gn6b.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:15Z",
      "native_id": "10.3389/fimmu.2026.1934039",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1934039/full"
    },
    {
      "first_seen": "2026-10-30T12:19:57Z",
      "native_id": "MED:42903181",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42903181"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "53L10 T-cell engager tribody for immunotherapy of multiple solid tumors",
  "title_text": "53L10 T-cell engager tribody for immunotherapy of multiple solid tumors",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:57Z",
  "url": "https://research.draconitic.com/paper/03cejw790gn6b",
  "venue": "Frontiers in Immunology",
  "versions": []
}